Figure 2.

oHSV single and oHSV + anti-PD1 combination therapy results in increased CD8+ T cells without an increase in regulatory T cells, similar in both models.

Mice treated as in Figure 1A and sacrificed 3 days after the final dose of oHSV or PBS with a single dose of anti-PD-1 antibody or control antibody given. Single-cell suspensions were obtained from isolated tumors, stained, and then analyzed via flow cytometry. Data show mean and standard error of the mean (SEM, n = 4 per treatment group). Statistical analysis was performed by one-way ANOVA with Tukey-adjusted post hoc tests (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). NK: Natural killer cells; Treg: T-regulatory cells; TAM: Tumor-associated macrophage; PD-1: Programmed cell death 1; CTLA-4: Cytotoxic T-lymphocyte associated protein-4; LAG-3: lymphocyte activation gene-3; TIM-3: T cell immunoglobulin and mucin-domain containing-3.